Question follow-through · 94616
Obesity: Health
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the soft drinks industry levy on reducing obesity and related illnesses.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 25 Nov 2025
- Target answer date
- 27 Nov 2025
- Answer
- 11 Dec 2025 · 16 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Draft Code of Practice on Electronic and Workplace Ballots for Statutory Trade Union Ballots · 15 Jul 2026
- Draft Trade Unions (Permissible Means of Voting) and Employment Rights (Unfair Dismissal) (Amendment) Order 2026 · 15 Jul 2026
- Taxation (Energy and Vehicles) Bill Committee: New Clause 5 · 1 Jul 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
25 Nov 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the soft drinks industry levy on reducing obesity and related illnesses.
27 Nov 2025
Target answer date
Date supplied by the official written-questions record.
11 Dec 2025
Answer published
Government data shows that sugar levels in drinks in scope of the Soft Drinks Industry Levy (SDIL) reduced by 47% between 2015 and 2024, removing approximately 57,000 tonnes of sugar from these drinks. This has had benefits across all socio-economic group...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the compatibility of the PATHWAYS trial with the requirement that clinical trials minimise foreseeable risks to child development.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, whether the PATHWAYS trial is insured against potential (a) loss of fertility, (b) impaired bone or cognitive development and (c) other long-term harms.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what safeguarding measures are in place to ensure that families do not feel pressured into the PATHWAYS trial.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment he made of the potential merits of (a) a feasibility study and (b) external peer review of the PATHWAYS trial.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of including a control group of children who receive no puberty suppression in the PATHWAYS trial.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what therapeutic or psychosocial interventions must be provided before a child is considered for the PATHWAYS trial.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, for what reason the PATHWAYS trial follow up period is limited to two years.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what long term monitoring will be in place to track adult reproductive, sexual and psychological outcomes of PATHWAYS trial participants.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, how the PATHWAYS trial will distinguish true clinical effects from placebo or expectation effects in an open label design.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, whether (a) detransitioners and (b) whistleblowers were consulted in the design of the PATHWAYS trial.
Puberty Suppressing Hormones: Clinical Trials
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of completing the Data Linkage Study to help inform safe PATHWAYS trial design.
Puberty Suppressing Hormones
4 Dec 2025 · To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the potential impact of puberty suppression on levels of likelihood of progression to cross sex hormones.